MADISON, Wis., Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023.
First Quarter Fiscal 2024 Summary
Other Recent Operational Highlights
"We delivered another strong quarter of revenue growth and margin expansion with successful execution against our strategic growth agenda," said Suzanne Winter, Chief Executive Officer. "I am very pleased with our strong start to the fiscal year, which includes key new product introductions and regulatory milestones that I believe will be the catalysts for increased use and adoption of our technology. We remain committed to providing medical care teams with innovative products and services that deliver value and close gaps in access to advanced radiotherapy treatments."
Fiscal First Quarter Results
Total net revenue in the first quarter of fiscal 2024 was $103.9 million, compared to $96.5 million in the prior fiscal year first quarter. Product revenue in the first quarter of fiscal 2024 was $53.4 million, compared to $44.6 million in the prior fiscal year first quarter. Service revenue in the first quarter of fiscal 2024 was $50.5 million, compared to $51.9 million in the prior fiscal year first quarter.
Total gross profit in the first quarter of fiscal 2024 was $39.5 million, or 38.0 percent of total net revenue, compared to total gross profit of $34.6 million, or 35.9 percent of total net revenue, in the prior fiscal year first quarter.
Operating expenses in the first quarter of fiscal 2024 were $37.3 million, compared to $36.8 million in the prior fiscal year first quarter.
Net loss in the first quarter of fiscal 2024 was $3.0 million, or $0.03 per share, compared to a net loss of $5.4 million, or $0.06 per share, in the prior fiscal year first quarter. Adjusted EBITDA in the first quarter of fiscal 2024 was $6.5 million, compared to $1.9 million in the prior fiscal year first quarter.
Gross product orders in the first quarter of fiscal 2024 totaled $63.7 million compared to $69.8 million in the prior fiscal year first quarter. Order backlog as of September 30, 2023 was $489.0 million, approximately 9.2 percent lower than at the end of the prior fiscal year first quarter.
Cash, cash equivalents, and short-term restricted cash were $77.4 million as of September 30, 2023, a decrease of $12.5 million from June 30, 2023.
Fiscal Year 2024 Financial Guidance
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The company is reaffirming guidance for fiscal year 2024 as follows:
Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, provision for income taxes, and ERP and ERP related expenditures. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2024 as well as recent corporate developments. Conference call dial-in information is as follows:
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 7621845. An archived webcast will also be available on Accuray's website until Accuray announces its results for the second quarter of fiscal 2024.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA, and net revenue on a constant currency basis.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, ERP and ERP related expenditures, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the effect of the global economic environment and the COVID-19 pandemic on the company and the market in general, including with respect to the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; delivering on the company's strategic growth plan, progressing against long-term strategic goals, and continuing adoption of its technologies; the company's ability to execute on margin and profitability expansion initiatives; expectations regarding commercial strategy and execution as well as growth opportunities; expectations regarding the market in China, the company's China joint venture and the Tomo-C product as well as expectations with respect to other strategic partnerships, including expected timing of regulatory clearances; expectations related to the markets in which the company operates; expectations regarding new product introductions and innovations and their effect on use and adoption of the company's products as well as revenue growth and EBITDA expansion; expectations with respect to the company's cost savings initiatives, including its reduction in global workforce and any related costs; expectations regarding backlog; and the company's ability to continue to build a stronger business and make investments that deliver value to customers and shareholders as well as advance patient care and close gaps in access to advanced radiotherapy treatments. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on September 7, 2023 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
* VitalHold™ availability is subject to regulatory clearance or approval in some markets
** Cenos is 510(k) pending. The solution is not available for sale in the USA. It is not CE marked and availability is subject to regulatory clearance or approval in some markets.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Accuray Incorporated Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2023 | 2022 | |||||||
Net revenue: | ||||||||
Products | $ | 53,350 | $ | 44,623 | ||||
Services | 50,542 | 51,870 | ||||||
Total net revenue | 103,892 | 96,493 | ||||||
Cost of revenue: | ||||||||
Cost of products | 35,699 | 28,850 | ||||||
Cost of services | 28,700 | 33,046 | ||||||
Total cost of revenue | 64,399 | 61,896 | ||||||
Gross profit | 39,493 | 34,597 | ||||||
Operating expenses: | ||||||||
Research and development | 14,013 | 14,092 | ||||||
Selling and marketing | 10,244 | 10,795 | ||||||
General and administrative | 13,023 | 11,892 | ||||||
Total operating expenses | 37,280 | 36,779 | ||||||
Income (loss) from operations | 2,213 | (2,182) | ||||||
Income (loss) from equity method investment, net | 431 | (368) | ||||||
Other expense, net | (3,681) | (2,558) | ||||||
Loss before provision for income taxes | (1,037) | (5,108) | ||||||
Provision for income taxes | 1,932 | 341 | ||||||
Net loss | $ | (2,969) | $ | (5,449) | ||||
Net loss per share - basic and diluted | $ | (0.03) | $ | (0.06) | ||||
Weighted average common shares used in computing loss per share: | ||||||||
Basic and diluted | 96,555 | 93,529 | ||||||
Accuray Incorporated Condensed Consolidated Balance Sheets (in thousands) (Unaudited) | ||||||||
September 30, | June 30, | |||||||
2023 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 76,918 | $ | 89,402 | ||||
Restricted cash | 524 | 524 | ||||||
Accounts receivable, net | 77,370 | 74,777 | ||||||
Inventories | 149,977 | 145,150 | ||||||
Prepaid expenses and other current assets | 28,798 | 27,612 | ||||||
Deferred cost of revenue | 560 | 568 | ||||||
Total current assets | 334,147 | 338,033 | ||||||
Property and equipment, net | 24,963 | 20,926 | ||||||
Investment in joint venture | 13,121 | 15,128 | ||||||
Operating lease right-of-use assets, net | 24,378 | 25,853 | ||||||
Goodwill | 57,656 | 57,681 | ||||||
Intangible assets, net | 163 | 210 | ||||||
Long-term restricted cash | 1,249 | 1,276 | ||||||
Other assets | 21,153 | 20,107 | ||||||
Total assets | $ | 476,830 | $ | 479,214 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 34,877 | $ | 33,739 | ||||
Accrued compensation | 26,496 | 23,793 | ||||||
Operating lease liabilities, current | 6,077 | 4,151 | ||||||
Other accrued liabilities | 36,634 | 38,271 | ||||||
Customer advances | 19,372 | 20,777 | ||||||
Deferred revenue | 71,764 | 72,185 | ||||||
Short-term debt | 6,229 | 5,721 | ||||||
Total current liabilities | 201,449 | 198,637 | ||||||
Operating lease liabilities, non-current | 22,806 | 23,602 | ||||||
Long-term other liabilities | 4,900 | 4,675 | ||||||
Deferred revenue, non-current | 26,939 | 27,079 | ||||||
Long-term debt | 169,792 | 171,562 | ||||||
Total liabilities | 425,886 | 425,555 | ||||||
Equity: | ||||||||
Common stock | 97 | 97 | ||||||
Additional paid-in capital | 557,668 | 555,276 | ||||||
Accumulated other comprehensive income (loss) | (1,716) | 422 | ||||||
Accumulated deficit | (505,105) | (502,136) | ||||||
Total equity | 50,944 | 53,659 | ||||||
Total liabilities and equity | $ | 476,830 | $ | 479,214 | ||||
Accuray Incorporated Summary of Orders and Backlog (in thousands, except book to bill ratio) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2023 | 2022 | |||||||
Gross Orders | $ | 63,734 | $ | 69,848 | ||||
Net Orders | 31,740 | 19,571 | ||||||
Order Backlog | 489,031 | 538,447 | ||||||
Book to bill ratio (a) | 1.2 | 1.6 | ||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period | ||||||||
Accuray Incorporated Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) (in thousands) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2023 | 2022 | |||||||
GAAP net loss | $ | (2,969) | $ | (5,449) | ||||
Depreciation and amortization (a) | 1,251 | 1,176 | ||||||
Stock-based compensation | 2,392 | 2,916 | ||||||
Interest expense, net (b) | 2,628 | 2,256 | ||||||
Provision for income taxes | 1,932 | 341 | ||||||
ERP and ERP related expenditures | 1,270 | 655 | ||||||
Adjusted EBITDA | $ | 6,504 | $ | 1,895 | ||||
(a) consists of depreciation, primarily on property and equipment as well as amortization of intangibles. | ||||||||
(b) consists primarily of interest expense associated with outstanding debt. | ||||||||
Accuray Incorporated Forward-Looking Guidance Reconciliation of Projected Net Income (Loss) to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) (in thousands) (Unaudited) | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net income (loss) | $ | (1,000) | $ | 2,000 | ||||
Depreciation and amortization (a) | 4,500 | 4,500 | ||||||
Stock-based compensation | 10,500 | 10,500 | ||||||
Interest expense, net (b) | 10,000 | 10,000 | ||||||
Provision for income taxes | 2,000 | 2,000 | ||||||
ERP and ERP related expenditures | 1,000 | 1,000 | ||||||
Adjusted EBITDA | $ | 27,000 | $ | 30,000 | ||||
(a) consists of depreciation, primarily on property and equipment as well as amortization of intangibles. | ||||||||
(b) consists primarily of interest expense associated with outstanding debt. | ||||||||
| Last Trade: | US$1.83 |
| Daily Change: | -0.04 -2.14 |
| Daily Volume: | 725,050 |
| Market Cap: | US$181.610M |
September 10, 2024 August 27, 2024 August 14, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
